Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
AVLV vs XBI: how they differ
AVLV and XBI hold 1% of their weight in the same names, and XBI returned more over the year.
Avantis U.S. Large Cap Value ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, AVLV and XBI hold 1% of their money in the same securities at the same weight.
| Holding | AVLV | XBI |
|---|---|---|
| Gilead Sciences Inc | 1.29% | 0.97% |
| Exelixis Inc | 0.26% | 0.96% |
| United Therapeutics Corp | 0.08% | 0.93% |
| Only in AVLV | Only in XBI |
|---|---|
| Micron Technology Inc 4.57% | Apogee Therapeutics Inc 1.49% |
| Amazon.com Inc 3.18% | Moderna Inc 1.41% |
| Apple Inc 3.17% | Twist Bioscience Corp 1.41% |
| Meta Platforms Inc 2.74% | Oruka Therapeutics Inc 1.38% |
| Exxon Mobil Corp 2.59% | Kymera Therapeutics Inc 1.36% |
| Caterpillar Inc 2.53% | Viking Therapeutics Inc 1.31% |
| Lam Research Corp 2.52% | Praxis Precision Medicines Inc 1.29% |
| Costco Wholesale Corp 2.06% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| AVLV Avantis U.S. Large Cap Value ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Avantis | State Street |
| What it is | U.S. Large Cap Value | SPDR S&P Biotech |
| Total return, 1 year | +31.0% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +13.5 pts | +46.5 pts |
| Expense ratio | 0.15% | 0.35% |
| Already in the S&P 500 | 84.5% | 8.5% |
| Holdings | 275 | 150 |
AVLV in plain words
AVLV is an index equity fund tracking the U.S. Large Cap Value. Over the year to Sep 11, 2026 it returned +31.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.15% a year. By its holdings filed for May 31, 2026, 84% of the fund by weight is stocks the S&P 500 also holds, across 275 positions, with the top ten at 26.9%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, AVLV or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, AVLV returned +31.0% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, AVLV or XBI?
- AVLV charges 0.15% a year and XBI charges 0.35%, so AVLV is cheaper. Fees come from each fund's prospectus.
- How much do AVLV and XBI overlap with the S&P 500?
- By their latest filed holdings, 84% of AVLV and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 1% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, AVLV against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/AVLV-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources